Taiwan Ko-Chung Lin, founder and CEO of PharmaEssentia, documents the main specificities of the company’s groundbreaking ropeginterferon alfa-2b, a once-every-two-week interferon displaying a unique toxicity profile. In this regard, Mr. Lin also provides insights into PharmaEssentia’s approach to the upcoming launch of this product into the US market as well as…
See our Cookie Privacy Policy Here